NAD+ for anti-aging: the longevity molecule

Key takeaways

• NAD+ levels decline 40-60% between ages 40 and 60, driven largely by increased CD38 enzyme activity
• Sirtuins (SIRT1-7) depend on NAD+ as a substrate to regulate gene expression, DNA repair, and mitochondrial health
• Animal studies consistently show that restoring NAD+ levels extends healthspan and, in some models, lifespan
• Human clinical trials confirm that NAD+ precursors safely raise blood NAD+ levels, though longevity-specific endpoints are still being studied
• NAD+ injections deliver the molecule directly into tissue, bypassing the digestive losses of oral supplements
• The anti-aging case for NAD+ is strong in theory and animal data, but human longevity trials are years away from completion

NAD+ has become one of the most studied molecules in aging research over the past decade. The reason is simple: it sits at the intersection of nearly every cellular process that degrades with age. Energy production, DNA repair, gene regulation, inflammation. All of them depend on adequate NAD+ levels, and all of them suffer when those levels drop [1].

As the NAD injections guide explains, NAD injections deliver nicotinamide adenine dinucleotide directly into tissue, bypassing the gut entirely. But before getting into delivery methods, it helps to understand why NAD+ matters for aging in the first place, and what the actual evidence says.

Why NAD+ declines with age

The NAD+ decline during aging is not just gradual wear and tear. It is driven by specific biological mechanisms, and the primary culprit is an enzyme called CD38.

CD38 is an ectoenzyme that degrades NAD+. Its expression increases with age, and a 2016 study in Cell Metabolism by Camacho-Pereira et al. showed that CD38 activity is the dominant driver of age-related NAD+ decline in mice. When the researchers knocked out CD38, the aged mice maintained youthful NAD+ levels and showed preserved mitochondrial function [2].

In humans, the decline is substantial. A 2021 review in Nature Reviews Molecular Cell Biology documented that tissue NAD+ concentrations fall significantly during middle age, with estimates ranging from 40-60% reduction by age 60 [3]. This is not a subtle shift. It represents a fundamental change in the cellular environment.

Other factors contribute. PARP enzymes, which repair damaged DNA, consume NAD+ every time they activate. As DNA damage accumulates with age, PARPs consume more NAD+, creating a vicious cycle: more damage means more NAD+ consumption, which means less NAD+ available for other protective functions like sirtuin activation [4].

Chronic inflammation also drives NAD+ depletion. Inflammatory signaling upregulates CD38 expression, which accelerates NAD+ breakdown. This connection between inflammation and NAD+ decline helps explain why metabolic diseases, obesity, and chronic stress all correlate with lower NAD+ levels.

Sirtuins: the NAD+-dependent longevity regulators

Sirtuins are a family of seven proteins (SIRT1 through SIRT7) that regulate gene expression, metabolism, and stress responses. They have been at the center of longevity research since the early 2000s, and every one of them requires NAD+ as a co-substrate to function [5].

Think of NAD+ as fuel for sirtuins. When NAD+ is abundant, sirtuins are active. When it drops, sirtuin activity decreases, and the downstream effects cascade through multiple systems.

SIRT1 is the most studied sirtuin for longevity. It deacetylates proteins involved in DNA repair, mitochondrial biogenesis, and glucose metabolism. SIRT1 activation mimics some of the metabolic effects of caloric restriction, which remains the most consistent intervention for extending lifespan across species [5].

SIRT3 operates inside mitochondria. It regulates the enzymes of the electron transport chain and the citric acid cycle, directly influencing how efficiently cells produce ATP. The 2016 CD38 study showed that age-related NAD+ decline impairs SIRT3 activity specifically, leading to mitochondrial dysfunction [2].

SIRT6 maintains genome stability. It participates in DNA double-strand break repair and telomere maintenance. Mice overexpressing SIRT6 live longer; mice lacking it show accelerated aging [5].

The connection between NAD+, sirtuins, and aging is why researchers like David Sinclair at Harvard have championed NAD+ replenishment as a longevity strategy. Sinclair’s lab published early work showing that raising NAD+ levels in aged mice activated SIRT1 and reversed markers of aging in muscle and brain tissue. His research contributed significantly to the current interest in NAD+ supplementation for aging, though he has also been transparent about the gap between mouse data and human proof [6].

DNA repair and NAD+

Every day, each cell in your body experiences tens of thousands of DNA damage events from normal metabolic activity, UV exposure, and environmental toxins. The repair machinery that fixes this damage depends heavily on NAD+.

PARP1, the primary DNA damage sensor, detects breaks in the DNA strand and recruits repair proteins to the site. Each repair event consumes NAD+ molecules. Under normal conditions, this is manageable. But with aging, two things happen simultaneously: DNA damage increases, and NAD+ supply decreases [4].

A 2026 review in Aging Cell by Bohr highlighted that this PARP-NAD+ axis is particularly relevant in premature aging disorders. In conditions like Werner syndrome and Cockayne syndrome, where DNA repair is genetically impaired, NAD+ depletion is accelerated and measurable. Supplementing NAD+ in these patients showed improved DNA repair capacity and mitochondrial function [4].

The Werner syndrome trial is especially informative. A 2025 double-blind, randomized, crossover trial gave Werner syndrome patients 1,000 mg of nicotinamide riboside (NR) daily for 26 weeks. NR improved arterial stiffness (measured by cardio-ankle vascular index), reduced skin ulcer area, and showed a trend toward preserved kidney function [7].

These are patients with extreme NAD+ depletion. The question for healthy aging is whether people with normal, age-related NAD+ decline see similar benefits at smaller magnitudes. That question is being studied but not yet definitively answered.

Mitochondrial function and cellular energy

Mitochondria produce about 90% of the energy your cells use. NAD+ is required at multiple steps of this process, accepting and donating electrons through glycolysis, the citric acid cycle, and the electron transport chain [1].

When NAD+ drops, mitochondrial efficiency declines. Cells produce less ATP per unit of fuel. This shows up clinically as fatigue, reduced exercise capacity, and slower recovery. It also creates a secondary problem: inefficient mitochondria produce more reactive oxygen species (ROS), which cause oxidative damage, which triggers more PARP activation, which consumes more NAD+.

Animal studies have been consistent on this point. Restoring NAD+ levels in aged mice improves mitochondrial membrane potential, increases ATP production, and reduces oxidative stress markers [2, 3]. The NMN-treated aged mice in multiple studies show mitochondrial profiles resembling those of younger animals.

In humans, the data is more limited but directional. The 2026 heart failure trial provides an interesting data point. Researchers gave 180 patients with ischemic cardiomyopathy either IV NAD+ or placebo for 7 days. The NAD+ group showed significantly improved left ventricular ejection fraction (45.44% vs 42.44%, P = 0.024), suggesting that NAD+ can measurably improve cardiac energy output even in severely compromised hearts [8].

For healthy adults, the connection between NAD+ and day-to-day energy is frequently reported anecdotally by patients using NAD injections, though controlled trial data on subjective energy in healthy populations remains limited.

What the animal longevity data shows

The animal data on NAD+ and lifespan is compelling, with a few important caveats.

A 2024 preprint reported that long-term NMN supplementation increased lifespan in mice in a sex-dependent manner, with female mice showing more consistent benefits [9]. Earlier studies showed that NMN improved glucose tolerance, reduced age-related weight gain, and enhanced physical activity in aged mice without extending maximum lifespan in all models.

Worm studies using C. elegans showed that NAD+ pathway activation via sirtuin overexpression extended lifespan by 10-50%, depending on the experimental conditions [5]. These effects tracked directly with NAD+ availability.

The caveat is always the same: mice are not people. Mice live 2-3 years, their metabolic rate is dramatically higher, and their NAD+ decline follows a compressed timeline. Whether restoring NAD+ in a 55-year-old human produces the same proportional benefits seen in 18-month-old mice is genuinely unknown.

That said, the consistency of the animal data across species (yeast, worms, flies, mice) and across interventions (genetic, pharmacological, dietary) is notable. Few molecules show such reproducible effects on aging hallmarks across so many models.

Human clinical evidence

Human trials on NAD+ precursors have confirmed safety and bioavailability. The clinical efficacy story is still being written.

A 2018 crossover trial showed that 1,000 mg of NR daily for 6 weeks safely elevated blood NAD+ levels by approximately 60% in healthy middle-aged and older adults [10]. The study also found trends toward reduced blood pressure and arterial stiffness, though it was not powered to detect clinical endpoints.

The 2023 multicenter NMN trial randomized 80 healthy adults to 300, 600, or 900 mg NMN daily for 60 days. All NMN doses significantly increased blood NAD+ and improved six-minute walking distance (P < 0.01). Biological age markers increased in the placebo group but remained stable in all NMN groups (P < 0.05) [11].

A 2026 study in Nature Metabolism directly compared NR, NMN, and nicotinamide in 65 healthy participants. Both NR and NMN comparably increased circulatory NAD+ over 14 days. The study revealed that both precursors work partly through gut microbial conversion to nicotinic acid, which then enters the Preiss-Handler pathway [12].

None of these trials measured lifespan or long-term aging outcomes. They measured biomarkers and short-term functional endpoints. True longevity trials would need to follow thousands of people for decades, and those studies have not been done.

NAD+ in the broader anti-aging peptide ecosystem

NAD+ therapy does not exist in isolation. Many patients pursuing longevity protocols combine NAD+ with other interventions that target different aging pathways.

GHK-Cu is a copper peptide that supports collagen synthesis and has shown anti-aging effects on skin and tissue remodeling. While NAD+ works at the metabolic and genomic level, GHK-Cu operates more directly on structural tissue repair.

Epitalon is a synthetic tetrapeptide studied for its effects on telomerase activity. Telomere shortening is one of the hallmarks of aging, and some longevity protocols combine NAD+ (for metabolic and DNA repair support) with epitalon (for telomere maintenance).

The peptides anti-aging guide covers the broader range of peptides studied for longevity. The common thread is that aging is multi-factorial, and no single intervention addresses every pathway. NAD+ addresses the metabolic and genomic repair axes; other peptides target structural, hormonal, or telomeric pathways.

For patients interested in the cognitive benefits specifically, peptides for cognitive function covers compounds that may complement NAD+‘s neuroprotective effects.

How to get NAD+ for anti-aging

NAD+ injections require a prescription from a licensed provider. The NAD+ is sourced from compounding pharmacies that prepare it under sterile conditions.

Most patients pursuing NAD+ for anti-aging start with a telehealth consultation to discuss goals, review bloodwork, and determine appropriate dosing. The NAD injection dosage guide covers typical protocols, which usually start at 100-200 mg subcutaneously 2-3 times per week.

Cost varies significantly by provider and delivery method. Our NAD injection cost breakdown covers what to expect, but subcutaneous self-injection programs typically run $200-500 per month.

For those considering oral precursors as a starting point, the NAD+ vs NMN vs NR comparison can help you evaluate the options.

Frequently asked questions

Does NAD+ actually slow aging?▼

NAD+ replenishment slows multiple aging processes in animal models, including mitochondrial decline, DNA damage accumulation, and sirtuin dysfunction. In humans, NAD+ precursors safely raise NAD+ levels and improve some functional markers like walking distance and biological age scores [11]. Whether this translates to measurably slower aging over decades has not been tested in clinical trials.

What does David Sinclair say about NAD+?▼

Sinclair’s lab at Harvard published foundational research showing that raising NAD+ levels in aged mice reversed markers of aging in muscle, brain, and vascular tissue. He has been a prominent advocate for NAD+ supplementation and personally takes NMN. He has also acknowledged that human proof of longevity benefits requires longer-term clinical trials than what currently exists [6].

How long does it take for NAD+ to work for anti-aging?▼

Most patients report noticing changes in energy and mental clarity within 1-2 weeks of starting NAD+ injections. Biochemical changes (elevated blood NAD+ levels) occur within days. Whether the deeper anti-aging effects on DNA repair and mitochondrial function produce measurable health improvements likely requires months of consistent use. The clinical trials showing functional improvements used 6-12 week protocols [10, 11].

Is oral NMN enough for anti-aging, or do I need injections?▼

Oral NMN does raise blood NAD+ levels. The 2023 multicenter trial showed dose-dependent increases with 300-900 mg daily [11]. Injections bypass digestive losses and may achieve higher tissue concentrations, but no head-to-head trial has compared injectable NAD+ against oral NMN on aging-specific endpoints. Oral NMN is a reasonable starting point for most people, with injections as an option for those wanting more direct delivery.

Can NAD+ reverse aging?▼

“Reverse” is too strong for what the current evidence supports. NAD+ replenishment can restore some age-related functional decline in animal models and improve biomarkers in humans. Framing it as restoration of declining function is more accurate than reversal of aging itself. The biological clock studies are promising, but the effect sizes are modest and the follow-up periods are short [11].

What is the best age to start NAD+ supplementation?▼

NAD+ decline accelerates during the 40s and 50s [3]. Most longevity physicians recommend considering NAD+ supplementation around age 40, when the decline becomes functionally relevant. Some researchers argue for earlier intervention, but there is no clinical trial data comparing outcomes by starting age.

Are there risks to long-term NAD+ use for anti-aging?▼

Short-term safety data is reassuring. Multiple randomized trials of NR and NMN lasting 6-12 weeks have shown no serious adverse effects [10, 11, 12]. Long-term data (years of continuous use) does not exist yet. The theoretical concern is that NAD+ supports cell growth broadly, including potentially in precancerous cells, though no clinical evidence supports this concern. The NAD side effects guide covers known adverse effects.

How does NAD+ compare to other anti-aging interventions?▼

NAD+ targets metabolic and genomic aging pathways (sirtuins, DNA repair, mitochondria). It complements rather than replaces other evidence-based interventions: exercise (the single best anti-aging intervention), caloric restriction, sleep optimization, and stress management. Among supplements, NAD+ precursors have more clinical data than most anti-aging compounds. Among peptides, the peptides anti-aging guide compares options.

References

1. Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213. https://pubmed.ncbi.nlm.nih.gov/26785480/

2. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism. 2016;23(6):1127-1139. https://pubmed.ncbi.nlm.nih.gov/27304511/

3. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141. https://pubmed.ncbi.nlm.nih.gov/33353981/

4. Bohr VA. Promising results with NAD supplementation in rare diseases with premature aging and DNA damage. Aging Cell. 2026;25(1):e70319. https://pubmed.ncbi.nlm.nih.gov/41436848/

5. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014;24(8):464-471. https://pubmed.ncbi.nlm.nih.gov/24786309/

6. Imai S, Guarente L. It takes two to tango: NAD+ and sirtuins in aging/longevity control. NPJ Aging and Mechanisms of Disease. 2016;2:16017. https://pubmed.ncbi.nlm.nih.gov/28721271/

7. Shoji M, Kato H, Koshizaka M, et al. Nicotinamide riboside supplementation benefits in patients with Werner syndrome: a double-blind randomized crossover placebo-controlled trial. Aging Cell. 2025;24(8):e70093. https://pubmed.ncbi.nlm.nih.gov/40459998/

8. Yu X, Xu J, Cao J, et al. Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: a randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs. 2026;26(1):97-106. https://pubmed.ncbi.nlm.nih.gov/40954388/

9. Long-term NMN treatment increases lifespan and healthspan in mice in a sex-dependent manner. bioRxiv. 2024. https://pubmed.ncbi.nlm.nih.gov/38979132/

10. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. https://pubmed.ncbi.nlm.nih.gov/29599478/

11. Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. https://pubmed.ncbi.nlm.nih.gov/36482258/

12. Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. 2026;8(1):62-73. https://pubmed.ncbi.nlm.nih.gov/41540253/